Mgmt expression correlates with response rate and survival in patients with inoperable glioblastoma (GBM) treated with neoadjuvant temozolomide (TMZ)

被引：0
|
作者：
Barrie, M.
Eudes, N.
Boucard, C.
Metellus, P.
Fuentes, S.
Honoré, S.
Dufour, H.
Figarella-Branger, D.
Chinot, O.
机构：
[1] CHU Timone, Marseille, France
[2] Fac Med Nord, Marseille, France
来源：
NEURO-ONCOLOGY | 2006年 / 8卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：352 / 352
页数：1
相关论文
共 50 条
  • [41] A prospective analysis of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) in glioblastoma (GBM) patients (PTS) treated with RT and Temozolomide (TMZ)
    Bergo, E.
    Bergo, E.
    Lombardi, G.
    Del Bianco, P.
    Berti, F.
    Bellu, L.
    Pambuku, A.
    Zagonel, V.
    ANNALS OF ONCOLOGY, 2016, 27
  • [42] A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).
    Khasraw, Mustafa
    McDonald, Kerrie Leanne
    Rosenthal, Mark
    Lwin, Zarnie
    Ashley, David M.
    Wheeler, Helen
    Barnes, Elizabeth
    Koh, Eng-Siew
    Foote, Matthew C.
    Buckland, Michael
    Fisher, Lauren
    Leonard, Robyn
    Hall, Merryn
    Yip, Sonia
    Simes, John
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] A prospective analysis of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) in glioblastoma (GBM) patients (PTS) treated with RT and Temozolomide (TMZ)
    Bergo, Eleonora
    PSYCHO-ONCOLOGY, 2016, 25 (SP. S3) : 161 - 161
  • [44] PHASE III TRIAL OF TUMOR TREATING FIELDS (TTFIELDS) TOGETHER WITH TEMOZOLOMIDE (TMZ) COMPARED TO TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Farber, Ori
    Weinberg, Uri
    Palti, Yoram
    NEURO-ONCOLOGY, 2013, 15 : 76 - 77
  • [45] MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
    Consolación Melguizo
    Jose Prados
    Beatriz González
    Raul Ortiz
    Angel Concha
    Pablo Juan Alvarez
    Roberto Madeddu
    Gloria Perazzoli
    Jaime Antonio Oliver
    Rodrigo López
    Fernando Rodríguez-Serrano
    Antonia Aránega
    Journal of Translational Medicine, 10
  • [46] A prospective analysis of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) in glioblastoma (GBM) patients (PTS) treated with RT and temozolomide (TMZ)
    Bergo, E.
    Lombardi, G.
    Del Bianco, P.
    Berti, F.
    Bellu, L.
    Pambuku, A.
    Zagonel, V.
    ANNALS OF ONCOLOGY, 2016, 27
  • [47] MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
    Melguizo, Consolacion
    Prados, Jose
    Gonzalez, Beatriz
    Ortiz, Raul
    Concha, Angel
    Juan Alvarez, Pablo
    Madeddu, Roberto
    Perazzoli, Gloria
    Antonio Oliver, Jaime
    Lopez, Rodrigo
    Rodriguez-Serrano, Fernando
    Aranega, Antonia
    JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
  • [48] NUTMEG: A randomised phase II study of nivolumab and temozolomide (TMZ) versus TMZ alone in elderly patients with newly diagnosed glioblastoma (GBM): Trial in progress
    Khasraw, Mustafa
    McDonald, Kerrie L.
    Yip, Sonia
    Verhaak, Roel
    Heimberger, Amy
    Hall, Merryn
    Fisher, Lauren
    Barnes, Elizabeth
    Rosenthal, Mark
    Gedye, Craig
    Hovey, Elizabeth
    Ellingson, Benjamin M.
    Simes, John
    Tongela, Annette
    Wheeler, Helen
    Koh, Eng-Siew
    Gan, Hui
    Back, Michael
    Lwin, Zarnie
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 196 - 197
  • [49] NUTMEG: A RANDOMISED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM): TRIAL IN PROGRESS
    Khasraw, Mustafa
    McDonald, Kerrie
    Yip, Sonia
    Verhaak, Roel
    Heimberger, Amy
    Hall, Merryn
    Fisher, Lauren
    Barnes, Elizabeth
    Rosenthal, Mark
    Gedye, Craig
    Hovey, Elizabeth
    Ellingson, Benjamin
    Simes, John
    Tognela, Annette
    Koh, Eng-Siew
    Gan, Hui
    Back, Michael
    Lwin, Zarnie
    NEURO-ONCOLOGY, 2018, 20 : 235 - 235
  • [50] MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
    Gonzalez-Astorga, B.
    Luque, R.
    Castellon, V.
    Gonzalez, E.
    Sanchez, C.
    Soberino, J.
    Gonzalez, C.
    Ruiz, J.
    Zurita, M.
    Delgado, J. R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S794 - S794
12345